The Anticancer Effect of Cannabinoid 2 Agonist L-759,633 on C6 and SH-SY5Y Cell Lines

Year 2021, Volume: 2 Issue: 3, 6 - 13, 30.09.2021

Zıad Joha , Fatih Yulak , Ayşegül Öztürk , Bilal Şahin , Şahin Yıldırım

https://doi.org/10.51972/tfsd.929180

Cited By: 2

Abstract

Purpose: Previous studies have shown that cannabinoid 2 agonists have anticancer effects on different cancer cell lines. However, the effect of L-759,633 on the C6 and SH-SY5Y cell lines is still unclear. The current study was designed to investigate the potential cytotoxic effects of a cannabinoid 2 agonist L-759,633 on the C6 and SH-SY5Y cell lines.
Material and Methods: In this study, the C6 and SH-SY5Y cell lines were used. For each cell line two cell groups were prepared to examine the effect of L-759,633 on C6 glioma and SH-SY5Y cell death. It was not applied any treatment to the cells in the control groups. Various concentrations (5, 10, 20, 40 and 80 μM) of L-759,633 was applied to the cells in the L-759,633 groups. After 24 hours the cell viability was examined using XTT assay. Total oxidant status (TOS) and Total antioxidant status (TAS) in the cells were measured by commercial kits.
Results: L-759,633 at the concentrations of 5, 10, 20, 40 and 80 μM significantly decreased the cell viability in C6 cells (p < 0.001). It also significantly increased the TOS levels (p < 0.001) whereas didn’t alter the TAS levels (p > 0.05). On the other hand this agent did not reduce SH-SY5Y cell viability.
Conclusion: L-759,633 has antiproliferative effect on C6 cells. Additionally, one of the potential mechanisms involved in this effect is activation the oxidant generation. However this drug didn’t show antiproliferative effect on SH-SY5Y cell.
Keywords: L-759,633, Oxidative Stress, cell viability, C6 Glioma, SH-SY5Y cell.

Keywords

L-759,633, Oxidative Stress, C6 Glioma, SH-SY5Y cell

References

• Aggarwal, V., Tuli, H. S., Varol, A., Thakral, F., Yerer, M. B., Sak, K., Varol, M., Jain, A., Khan, M. A., & Sethi, G. (2019). Role of reactive oxygen species in cancer progression: Molecular mechanisms and recent advancements. In Biomolecules (Vol. 9, Issue 11). MDPI AG. https://doi.org/10.3390/biom9110735
• Blázquez, C., González-Feria, L., Álvarez, L., Haro, A., Casanova, M. L., & Guzmán, M. (2004). Cannabinoids inhibit the vascular endothelial growth factor pathway in gliomas. Cancer Research, 64(16), 5617–5623. https://doi.org/10.1158/0008-5472.CAN-03-3927
• Blázquez, C., Salazar, M., Carracedo, A., Lorente, M., Egia, A., González-Feria, L., Haro, A., Velasco, G., & Guzmán, M. (2008). Cannabinoids inhibit glioma cell invasion by down-regulating matrix metalloproteinase-2 expression. Cancer Research, 68(6), 1945–1952. https://doi.org/10.1158/0008-5472.CAN-07-5176
• Carracedo, A., Lorente, M., Egia, A., Blázquez, C., García, S., Giroux, V., Malicet, C., Villuendas, R., Gironella, M., González-Feria, L., Piris, M. Á., Iovanna, J. L., Guzmán, M., & Velasco, G. (2006). The stress-regulated protein p8 mediates cannabinoid-induced apoptosis of tumor cells. Cancer Cell, 9(4), 301–312. https://doi.org/10.1016/j.ccr.2006.03.005
• Casanova, M. L., Blázquez, C., Martínez-Palacio, J., Villanueva, C., Fernández-Aceñero, M. J., Huffman, J. W., Jorcano, J. L., & Guzmán, M. (2003). Inhibition of skin tumor growth and angiogenesis in vivo by activation of cannabinoid receptors. Journal of Clinical Investigation, 111(1), 43–50. https://doi.org/10.1172/jci16116
• Choi, M., Kim, W., Cheon, M. G., Lee, C. W., & Kim, J. E. (2015). Polo-like kinase 1 inhibitor BI2536 causes mitotic catastrophe following activation of the spindle assembly checkpoint in non-small cell lung cancer cells. Cancer Letters, 357(2), 591–601. https://doi.org/10.1016/j.canlet.2014.12.023
• Cianchi, F., Papucci, L., Schiavone, N., Lulli, M., Magnelli, L., Vinci, M. C., Messerini, L., Manera, C., Ronconi, E., Romagnani, P., Donnini, M., Perigli, G., Trallori, G., Tanganelli, E., Capaccioli, S., & Masini, E. (2008). Cannabinoid receptor activation induces apoptosis through tumor necrosis factor α-mediated ceramide de novo synthesis in colon cancer cells. Clinical Cancer Research, 14(23), 7691–7700. https://doi.org/10.1158/1078-0432.CCR-08-0799
• Cioni, C., Tassi, M., Marotta, G., Mugnaini, C., Corelli, F., & Annunziata, P. (2019). A Novel Highly Selective Cannabinoid CB2 Agonist Reduces in vitro Growth and TGF-beta Release of Human Glial Cell Tumors. Central Nervous System Agents in Medicinal Chemistry, 19(3), 206–214. https://doi.org/10.2174/1871524919666190923154351
• Den Boon, F. S., Chameau, P., Schaafsma-Zhao, Q., Van Aken, W., Bari, M., Oddi, S., Kruse, C. G., Maccarrone, M., Wadman, W. J., & Werkmana, T. R. (2012). Excitability of prefrontal cortical pyramidal neurons is modulated by activation of intracellular type-2 cannabinoid receptors. Proceedings of the National Academy of Sciences of the United States of America, 109(9), 3534–3539. https://doi.org/10.1073/pnas.1118167109
• Ellert-Miklaszewska, A., Grajkowska, W., Gabrusiewicz, K., Kaminska, B., & Konarska, L. (2007). Distinctive pattern of cannabinoid receptor type II (CB2) expression in adult and pediatric brain tumors. Brain Research, 1137(1), 161–169. https://doi.org/10.1016/j.brainres.2006.12.060
• Erel, O. (2004a). A novel automated method to measure total antioxidant response against potent free radical reactions. Clinical Biochemistry, 37(2), 112–119. https://doi.org/10.1016/j.clinbiochem.2003.10.014
• Erel, O. (2004b). A novel automated direct measurement method for total antioxidant capacity using a new generation, more stable ABTS radical cation. Clinical Biochemistry, 37(4), 277–285. https://doi.org/10.1016/j.clinbiochem.2003.11.015
• Erel, O. (2005). A new automated colorimetric method for measuring total oxidant status. Clinical Biochemistry, 38(12), 1103–1111. https://doi.org/10.1016/j.clinbiochem.2005.08.008
• Ergul, M., & Bakar-Ates, F. (2020). A specific inhibitor of polo-like kinase 1, GSK461364A, suppresses proliferation of Raji Burkitt’s lymphoma cells through mediating cell cycle arrest, DNA damage, and apoptosis. Chemico-Biological Interactions, 332. https://doi.org/10.1016/j.cbi.2020.109288
• Fernández-Ruiz, J., Romero, J., Velasco, G., Tolón, R. M., Ramos, J. A., & Guzmán, M. (2007). Cannabinoid CB2 receptor: a new target for controlling neural cell survival? In Trends in Pharmacological Sciences (Vol. 28, Issue 1, pp. 39–45). Trends Pharmacol Sci. https://doi.org/10.1016/j.tips.2006.11.001
• Fisher, T., Golan, H., Schiby, G., Prichen, S., Smoum, R., Moshe, I., Peshes-Yaloz, N., Castiel, A., Waldman, D., Gallily, R., Mechoulam, R., & Toren, A. (2016). In vitro and in vivo efficacy of non-psychoactive cannabidiol in neuroblastoma. Current Oncology, 23(2), S15–S22. https://doi.org/10.3747/co.23.2893
• Galanti, G., Fisher, T., Kventsel, I., Shoham, J., Gallily, R., Mechoulam, R., Lavie, G., Amariglio, N., Rechavi, G., & Toren, A. (2008). Δ9-Tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncologica, 47(6), 1062–1070. https://doi.org/10.1080/02841860701678787
• Galve-Roperh, I., Sánchez, C., Cortés, M. L., Del Pulgar, T. G., Izquierdo, M., & Guzmán, M. (2000). Anti-tumoral action of cannabinoids: Involvement of sustained ceramide accumulation and extracellular signal-regulated kinase activation. Nature Medicine, 6(3), 313–319. https://doi.org/10.1038/73171
• García, M. C., Cinquina, V., Palomo-Garo, C., Rábano, A., & Fernández-Ruiz, J. (2015). Identification of CB2 receptors in human nigral neurons that degenerate in Parkinson’s disease. Neuroscience Letters, 587, 1–4. https://doi.org/10.1016/j.neulet.2014.12.003
• Held-Feindt, J., Dorner, L., Sahan, G., Mehdorn, H. M., & Mentlein, R. (2006). Cannabinoid receptors in human astroglial tumors. Journal of Neurochemistry, 98(3), 886–893. https://doi.org/10.1111/j.1471-4159.2006.03911.x
• Jacobsson, S. O. P., Rongård, E., Stridh, M., Tiger, G., & Fowler, C. J. (2000). Serum-dependent effects of tamoxifen and cannabinoids upon C6 glioma cell viability. Biochemical Pharmacology, 60(12), 1807–1813. https://doi.org/10.1016/S0006-2952(00)00492-5
• Kleihues, P., Louis, D. N., Scheithauer, B. W., Rorke, L. B., Reifenberger, G., Burger, P. C., & Cavenee, W. K. (2002). The WHO classification of tumors of the nervous system. Journal of Neuropathology and Experimental Neurology, 61(3), 215–225. https://doi.org/10.1093/jnen/61.3.215
• Kovalchuk, O., & Kovalchuk, I. (2020). Cannabinoids as anticancer therapeutic agents. In Cell Cycle (Vol. 19, Issue 9, pp. 961–989). Taylor and Francis Inc. https://doi.org/10.1080/15384101.2020.1742952
• Lanciego, J. L., Barroso-Chinea, P., Rico, A. J., Conte-Perales, L., Callén, L., Roda, E., Gómez-Bautista, V., López, I. P., Lluis, C., Labandeira-García, J. L., & Franco, R. (2011). Expression of the mRNA coding the cannabinoid receptor 2 in the pallidal complex of Macaca fascicularis. Journal of Psychopharmacology, 25(1), 97–104. https://doi.org/10.1177/0269881110367732
• Ligresti, A., Bisogno, T., Matias, I., De Petrocellis, L., Cascio, M. G., Cosenza, V., D’Argenio, G., Scaglione, G., Bifulco, M., Sorrentini, I., & Di Marzo, V. (2003). Possible endocannabinoid control of colorectal cancer growth. Gastroenterology, 125(3), 677–687. https://doi.org/10.1016/S0016-5085(03)00881-3
• London, W. B., Castel, V., Monclair, T., Ambros, P. F., Pearson, A. D. J., Cohn, S. L., Berthold, F., Nakagawara, A., Ladenstein, R. L., Iehara, T., & Matthay, K. K. (2011). Clinical and biologic features predictive of survival after relapse of neuroblastoma: A report from the International Neuroblastoma Risk Group Project. Journal of Clinical Oncology, 29(24), 3286–3292. https://doi.org/10.1200/JCO.2010.34.3392
• Maher, E. A., Furnari, F. B., Bachoo, R. M., Rowitch, D. H., Louis, D. N., Cavenee, W. K., & DePinho, R. A. (2001). Malignant glioma: Genetics and biology of a grave matter. In Genes and Development (Vol. 15, Issue 11, pp. 1311–1333). Genes Dev. https://doi.org/10.1101/gad.891601
• Maris, J. M., Hogarty, M. D., Bagatell, R., & Cohn, S. L. (2007). Neuroblastoma. In Lancet (Vol. 369, Issue 9579, pp. 2106–2120). Lancet. https://doi.org/10.1016/S0140-6736(07)60983-0
• McAllister, S. D., Murase, R., Christian, R. T., Lau, D., Zielinski, A. J., Allison, J., Almanza, C., Pakdel, A., Lee, J., Limbad, C., Liu, Y., Debs, R. J., Moore, D. H., & Desprez, P. Y. (2011). Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis. Breast Cancer Research and Treatment, 129(1), 37–47. https://doi.org/10.1007/s10549-010-1177-4
• Onaivi, E. S., Ishiguro, H., Gu, S., & Liu, Q. R. (2012). CNS effects of CB2 cannabinoid receptors: Beyond neuro-immuno-cannabinoid activity. In Journal of Psychopharmacology (Vol. 26, Issue 1, pp. 92–103). J Psychopharmacol. https://doi.org/10.1177/0269881111400652
• Portella, G., Laezza, C., Laccetti, P., De Petrocellis, L., Di Marzo, V., & Bifulco, M. (2003). Inhibitory effects of cannabinoid CB1 receptor stimulation on tumor growth and metastatic spreading: actions on signals involved in angiogenesis and metastasis. The FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology, 17(12), 1771–1773. https://doi.org/10.1096/fj.02-1129fje
• Reardon, D. A., & Wen, P. Y. (2006). Therapeutic Advances in the Treatment of Glioblastoma: Rationale and Potential Role of Targeted Agents. The Oncologist, 11(2), 152–164. https://doi.org/10.1634/theoncologist.11-2-152
• Sánchez, C., de Ceballos, M. L., Gómez del Pulgar, T., Rueda, D., Corbacho, C., Velasco, G., Galve-Roperh, I., Huffman, J. W., Ramón Cajal, S., & Guzmán, M. (2001). Inhibition of Glioma Growth in Vivo by Selective Activation of the CB 2 Cannabinoid Receptor 1. In CANCER RESEARCH (Vol. 61).
• Schmöle, A. C., Lundt, R., Ternes, S., Albayram, Ö., Ulas, T., Schultze, J. L., Bano, D., Nicotera, P., Alferink, J., & Zimmer, A. (2015). Cannabinoid receptor 2 deficiency results in reduced neuroinflammation in an Alzheimer’s disease mouse model. Neurobiology of Aging, 36(2), 710–719. https://doi.org/10.1016/j.neurobiolaging.2014.09.019
• Sezer, Y., Jannuzzi, A. T., Huestis, M. A., & Alpertunga, B. (2021). In vitro assessment of the cytotoxic, genotoxic and oxidative stress effects of the synthetic cannabinoid JWH-018 in human SH-SY5Y neuronal cells. Toxicology Research, 9(6), 734–740. https://doi.org/10.1093/toxres/tfaa078
• Suebsoonthron, J., Jaroonwitchawan, T., Yamabhai, M., & Noisa, P. (2017). Inhibition of WNT signaling reduces differentiation and induces sensitivity to doxorubicin in human malignant neuroblastoma SH-SY5Y cells. Anti-Cancer Drugs, 28(5), 469–479. https://doi.org/10.1097/CAD.0000000000000478
• Taskiran, A. Ş., & Ergül, M. (2021). The Protective Effect of Hydralazine against Hydrogen Peroxide (H2O2)-Induced Oxidative Damage in C6 Glial Cell Line. Turkish Journal of Science and Health, 124–132.
• Taskiran, A. S., Ergul, M., Gunes, H., Ozturk, A., Sahin, B., & Ozdemir, E. (2021). The Effects of Proton Pump Inhibitors (Pantoprazole) on Pentylenetetrazole-Induced Epileptic Seizures in Rats and Neurotoxicity in the SH-SY5Y Human Neuroblastoma Cell Line. Cellular and Molecular Neurobiology, 41(1), 173–183. https://doi.org/10.1007/s10571-020-00956-6
• Türe, A., Ergül, M., Ergül, M., Altun, A., & Küçükgüzel, İ. (2020). Design, synthesis, and anticancer activity of novel 4-thiazolidinone-phenylaminopyrimidine hybrids. Molecular Diversity. https://doi.org/10.1007/s11030-020-10087-1
• Van Sickle, M. D., Duncan, M., Kingsley, P. J., Mouihate, A., Urbani, P., Mackie, K., Stella, N., Makriyannis, A., Piomelli, D., Davison, J. S., Marnett, L. J., Di Marzo, V., Pittman, Q. J., Patel, K. D., & Sharkey, K. A. (2005). Neuroscience: Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 310(5746), 329–332. https://doi.org/10.1126/science.1115740
• Vara, D., Salazar, M., Olea-Herrero, N., Guzmán, M., Velasco, G., & Díaz-Laviada, I. (2011). Anti-tumoral action of cannabinoids on hepatocellular carcinoma: Role of AMPK-dependent activation of autophagy. Cell Death and Differentiation, 18(7), 1099–1111. https://doi.org/10.1038/cdd.2011.32
• Velasco, G., Sánchez, C., & Guzmán, M. (2016). Anticancer mechanisms of cannabinoids. In Current Oncology (Vol. 23, Issue Suppl 2, pp. S23–S32). Multimed Inc. https://doi.org/10.3747/co.23.3080
• Velasco, Guillermo, Carracedo, A., Blázquez, C., Lorente, M., Aguado, T., Haro, A., Sánchez, C., Galve-Roperh, I., & Guzmán, M. (2007). Cannabinoids and gliomas. In Molecular Neurobiology (Vol. 36, Issue 1, pp. 60–67). Humana Press Inc. https://doi.org/10.1007/s12035-007-0002-5
• Velasco, Guillermo, Sánchez, C., & Guzmán, M. (2012). Towards the use of cannabinoids as antitumour agents. In Nature Reviews Cancer (Vol. 12, Issue 6, pp. 436–444). Nat Rev Cancer. https://doi.org/10.1038/nrc3247
• Wojcieszak, J., Krzemień, W., & Zawilska, J. B. (2016). JWH-133, a Selective Cannabinoid CB2 Receptor Agonist, Exerts Toxic Effects on Neuroblastoma SH-SY5Y Cells. Journal of Molecular Neuroscience, 58(4), 441–445. https://doi.org/10.1007/s12031-016-0726-7
• Zhang, H. Y., Gao, M., Liu, Q. R., Bi, G. H., Li, X., Yang, H. J., Gardner, E. L., Wu, J., & Xi, Z. X. (2014). Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Proceedings of the National Academy of Sciences of the United States of America, 111(46), E5007–E5015. https://doi.org/10.1073/pnas.1413210111